PTC Therapeutics to Acquire Fabry Gene Therapy Asset for $111 Million

Key Facts

In a move reflecting a strategic expansion into specialized treatments, PTC Therapeutics is seeking to acquire the ST-920 gene therapy asset for Fabry disease. The company plans to participate in a competitive bankruptcy auction to secure the program in a deal valued at approximately $111 million. According to reports, the acquisition aims to add a potential one-time treatment to the company's existing rare disease portfolio.

The proposed deal aligns with PTC's strategy to leverage its established global commercial and regulatory infrastructure. By acquiring the asset from Sangamo Therapeutics through the auction process, the company looks to strengthen its position in the gene therapy sector at a valuation driven by bankruptcy proceedings, potentially providing long-term strategic value in the specialty pharma market.

Based on available data, specific price levels for PTCT shares are currently unavailable in the database as of August 16, 2026. Investors are monitoring the bankruptcy auction results as a primary catalyst, while broader markets look toward global economic data such as the U.S. Inflation Rate, which was recently reported at 3.4% YoY per data from August 12, 2026.